Source: Biotech stocks have been one of the market’s hottest spots in recent years. But when markets get a sudden chill, as they did this month, big pharmaceutical shares are a better bet. Over the past four years, a broad index of biotech stocks has outperformed a pharmaceutical index by…...

Source: Forbes Last week I wrote a post about new data from BioMedTracker that show that the Food and Drug Administration, which once approved as few as 40% of new drugs submitted by industry, has been on a green-light-almost-everything jag, approving 89% of drug applications. What’s more, a closer look…...

Source: FierceHealthPayer The biggest for-profit health insurers continue to benefit from a low utilization trend among consumers, as most reported better-than-expected second-quarter earnings. The weak economy keeps consumers from seeing their doctors and avoiding hospitalizations, yet more people are signing up for health plans through the health insurance exchanges, Reuters…...

Source: Drug sales crossed a significant metric last year. They grew past $1 trillion. And for those industry insiders thinking global sales will taper off, a new report says think again. Expect sales to top $1.3 trillion in 2018. Recent years have been full of reports about the falloff in…...